Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 11/20 | 0.45 |
| ▸ | GRIN1 | Q05586 | 11/20 | 0.45 |
| ▸ | GRIN2B | Q13224 | 11/20 | 0.45 |
| ▸ | DDX3X | O00571 | 1/20 | 0.45 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
| ▸ | HSD17B13 | Q7Z5P4 | 1/20 | 0.43 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.41 |
| ▸ | MIF | P14174 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14324238 | 0.89 | MIF (0.49) | RXRAGRIN1GRIN2BDDX3XHDAC8 | |
| SCHEMBL14323567 | 0.88 | HDAC8 (0.59) | RXRAGRIN1GRIN2BDDX3XHDAC8 | |
| SCHEMBL14322139 | 0.87 | HDAC8 (0.54) | DDX3XHDAC8HDAC6MIF | |
| SCHEMBL14324230 | 0.86 | HDAC8 (0.55) | DDX3XHDAC8HDAC6MIF | |
| SCHEMBL14323957 | 0.82 | HDAC8 (0.56) | DDX3XHDAC8HDAC6MIF | |
| SCHEMBL14323975 | 0.81 | DRD2 (0.48) | RXRAGRIN1GRIN2BHDAC8HDAC6 | |
| SCHEMBL14322416 | 0.78 | DRD2 (0.50) | RXRAGRIN1GRIN2BDDX3XHDAC8 | |
| SCHEMBL14323393 | 0.78 | HDAC8 (0.58) | HDAC8HDAC6MIF | |
| SCHEMBL14324271 | 0.76 | HDAC8 (0.60) | RXRAGRIN1GRIN2BHDAC8HDAC6 | |
| SCHEMBL21974268 | 0.75 | RXRA (0.59) | RXRAGRIN1GRIN2BDDX3XMIF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8871728-B2 | Non-peptide macrocyclic histone deacetylese (HDAC) inhibitors and methods of making and using thereof | GEORGIA TECH RESEARCH CORPORATION (US) | 2014-10-28 | — | — | US | disclosed |
| US-20120329741-A1 | NON-PEPTIDE MACROCYCLIC HISTONE DEACETYLASE (HDAC) INHIBITORS AND METHODS OF MAKING AND USING THEREOF | GEORGIA TECH RESEARCH CORPORATION | 2012-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120329741-A1 | NON-PEPTIDE MACROCYCLIC HISTONE DEACETYLASE (HDAC) INHIBITORS AND METHODS OF MAKING AND USING THEREOF | HDAC5, HDAC3, HDAC1 | RXRA 1133/4885GRIN1 1712/4885GRIN2B 334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.